Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

@article{GarciaRomeu2014PsilocybinoccasionedME,
  title={Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.},
  author={Albert Garcia-Romeu and Roland R. Griffiths and Matthew W. Johnson},
  journal={Current drug abuse reviews},
  year={2014},
  volume={7 3},
  pages={
          157-64
        }
}
Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the context of cognitive behavioral therapy (CBT) for smoking cessation. Twelve of 15 participants (80%) demonstrated biologically verified… Expand
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
TLDR
Results suggest psychedelics may hold promise in treating tobacco addiction as potentially mediated by spiritual experience, changed priorities/values, and improved emotional regulation. Expand
Long-term follow-up of psilocybin-facilitated smoking cessation
TLDR
The results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence, adding to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Expand
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
TLDR
Both high-dose psilocybin groups showed large significant positive changes on longitudinal measures of interpersonal closeness, gratitude, life meaning/purpose, forgiveness, death transcendence, daily spiritual experiences, religious faith and coping, and community observer ratings. Expand
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
TLDR
The findings highlight the value of qualitative research in the psychopharmacological investigation of psychedelics and describe perceived connections between drug- and non-drug factors, and provide suggestions for future research trial design and clinical applications. Expand
Dose–response relationships of psilocybin-induced subjective experiences in humans
TLDR
Psilocybin intensified almost all characteristics of altered states of consciousness assessed with the given questionnaires, and the results may only apply to controlled laboratory experiments and not to recreational use. Expand
The American Journal of Drug and Alcohol Abuse Encompassing All Addictive Disorders
Background: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination withExpand
Potential Therapeutic Effects of Psilocybin
Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus withinExpand
Classic hallucinogens in the treatment of addictions
TLDR
A comprehensive review of both historical and recent clinical research on the use of classic hallucinogens in the treatment of addiction, selectively review other relevant research concerning hallucinogenic research, and suggest directions for future research are provided. Expand
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
TLDR
A method to score a “complete mystical experience” that was used in previous versions of the mystical experience questionnaire is validated in the MEQ30, and a stand-alone version of theMEQ30 is provided for use in future research. Expand
A potential role for psilocybin in the treatment of obsessive-compulsive disorder
  • E. Jacobs
  • Medicine
  • Journal of Psychedelic Studies
  • 2020
TLDR
Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
TLDR
An open-label pilot study administering moderate and high psilocybin doses within a structured 15-week smoking cessation treatment protocol demonstrated that 12 of 15 participants showed seven-day point prevalence abstinence at 6-month follow-up, substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies. Expand
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
TLDR
Under supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Expand
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
TLDR
When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences, and the ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences. Expand
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
TLDR
When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences that, at 14-month follow-up, were considered by volunteers to be among the most personally meaningful and spiritually significant of their lives. Expand
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
TLDR
Assessment of the effect of psilocybin on changes in the five broad domains of personality – Neuroticism, Extroversion, Openness, Agreeableness, and Conscientiousness found significant increases in Openness following a high-dose p silocybin session. Expand
Mindfulness training for smoking cessation: results from a randomized controlled trial.
TLDR
This initial trial of mindfulness training may confer benefits greater than those associated with current standard treatments for smoking cessation, as shown in the results of this randomized clinical trials. Expand
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
TLDR
This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety. Expand
Acute and post-acute behavioral and psychological effects of salvinorin A in humans
TLDR
The present results indicate similarities as well as differences between the subjective effects of S. divinorum and other hallucinogenic states beyond serotonergic mechanisms as a selective kappa opioid receptor agonist. Expand
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers
TLDR
It is demonstrated that acute treatment with psilocybin decreased amygdala reactivity during emotion processing and that this was associated with an increase of positive mood in healthy volunteers. Expand
Treatment of alcoholism using psychedelic drugs: a review of the program of research.
  • M. Mangini
  • Psychology, Medicine
  • Journal of psychoactive drugs
  • 1998
TLDR
The history of one branch of psychedelic research, the therapeutic use of LSD in the treatment of alcoholism, and of the events that led to the relabeling of the "hallucinogens" as drugs of abuse are explored. Expand
...
1
2
3
4
5
...